Journey Medical Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DERM research report →
Range $10.5 – $13
Price Chart
About the company
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc. ), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution.
- CEO
- Claude Maraoui
- IPO
- 2021
- Employees
- 58
- HQ
- Scottsdale, AZ, US
Get TickerSpark's AI analysis on DERM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $93.14M
- P/E
- -18.61
- Fwd P/E
- 10.48
- PEG
- -0.58
- P/S
- 1.40
- P/B
- 3.01
- EV/EBITDA
- 36.90
- Div Yield
- 0.00%
- Gross Margin
- 43.20%
- Op Margin
- -2.89%
- Net Margin
- -7.34%
- ROE
- -16.07%
- ROIC
- -3.47%
Latest fiscal year · YoY change
- Revenue
- $61.86M+10.2%
- Gross Profit
- $36.68M+4.0%
- Op Income
- $-8,172,000
- Net Income
- $-11,431,000+22.1%
- EPS
- $-0.47+34.7%
- OCF Growth
- -36.3%
- FCF Growth
- +48.4%
- 52W High
- $9.56
- 52W Low
- $3.21
- 50D MA
- $5.58
- 200D MA
- $6.34
- Beta
- 1.15
- RSI (14)
- 27
- Avg Volume
- 190.69K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Journey Medical posted another quarter of Emrosi-led growth, with revenue up 8%, gross margin expanding, and positive EBITDA for a second straight quarter as management pointed to more formulary wins ahead.· November 12, 2026
- Total revenue rose 8% year over year to $19 million, driven mainly by Emrosi, which generated $9 million in net revenue.
- Emrosi prescriptions reached about 40,000 in Q3, up from about 36,000 in Q2, and unique prescribers grew to over 5,000 from roughly 4,500.
- Gross margin improved to 69% from 67%, and GAAP net loss narrowed to $1.3 million, or $0.05 per share, from $3.9 million, or $0.14 per share.
- Management said a large national plan with over 25 million lives is expected to come on formulary in early 2027, with more plans likely to follow.
- The company ended Q3 with $22.3 million in cash and said it is considering, but not yet ready to give, formal 2027 guidance.
Q3 2026 total revenue was $19 million, up 8% from $15 million in Q3 2025. Net product sales increased 11% year over year, and Emrosi generated $9 million in net revenue. Gross margin was 69% versus 67% a year ago. SG&A was $12.6 million versus $12.1 million, including a one-time $1.7 million vendor dispute settlement. GAAP net loss improved to $1.3 million, or $0.05 per share, from $3.9 million, or $0.14 per share, in Q3 2025. The company said EBITDA and adjusted EBITDA were both positive, and adjusted EBITDA reflected net income of $3.5 million versus $1.4 million in the prior-year quarter. Cash was $22.3 million at quarter end, down from $24.1 million at December 31, 2025. For forward commentary, management expects Emrosi prescription growth, payer coverage, and ASP to continue improving, but did not provide formal 2027 revenue or EBITDA guidance.
Claude Maraoui struck an upbeat but measured tone, emphasizing that the quarter showed continued top-line growth, better profitability, and momentum behind Emrosi. He highlighted that the brand is gaining prescribers, refill rates are strong, and the product’s clinical profile and payer access are supporting broader adoption. He also said the company is focused on becoming net earnings and cash flow positive while continuing to invest in commercial execution and market access.
Joseph Benesch focused on the numbers and margin progression, citing $19 million of revenue, 69% gross margin, and a narrower GAAP net loss of $1.3 million. He said the $1.7 million vendor dispute settlement was a one-time, previously reserved cash outlay and that the business ended the quarter with $22.3 million in cash. He also said SG&A should be consistent or slightly lower as a percentage of revenue going forward even as the company keeps investing in sales force and growth programs.
Analysts pressed on the impact of the copay/bridging program change and whether October volatility would hurt Q4, and management said there was some short-term disruption but that the business was recovering and should stabilize within roughly 4 to 8 weeks. They also asked about the large national formulary win expected in early 2027; management said it covers over 25 million lives and should be a meaningful catalyst for revenue and ASP, though deductible resets could delay some of the benefit flowing through. Another key question was whether the company would issue formal 2027 guidance, and management said it is strongly considering it but wants to see how the new formulary wins and patient mix stabilize first.
The bull case from this call is that Emrosi is still early in its commercial ramp, with prescriptions, prescribers, and refills all moving higher. Management believes the brand is building critical mass, payer access is improving, and a major national formulary win plus additional plan wins could lift ASP and reimbursements in 2027. The company is also already producing positive EBITDA, suggesting operating leverage is starting to show through.
The main risks discussed were volatility from changes to the copay/bridging program, which management said can cause temporary dips before demand recovers. Management also acknowledged that deductible resets early in the year could delay some of the 2027 formulary benefit, and it has not yet committed to formal 2027 guidance. In addition, the company is still dependent on Emrosi’s momentum, and management said it may need to add more resources, which could pressure spend if growth does not scale as expected.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 51.5%
- Shares Outstanding
- 28.22M
- Float Shares
- 14.53M
of shares held by institutions
74 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tang Capital Management LLC | 1.61M | 0 |
| Punch & Associates Investment Management, Inc. | 858.08K | ▲ 322.08K |
| Vanguard Group Inc | 764.15K | ▲ 148.92K |
| Vanguard Capital Management LLC | 675.18K | 0 |
| Pale Fire Capital Se | 521.84K | ▼ 6.74K |
| First Eagle Investment Management, LLC | 483.21K | ▲ 483.21K |
| Summit Financial, LLC | 344.21K | ▼ 2.53K |
| Diametric Capital, LP | 284.45K | ▼ 11.21K |
| Ikarian Capital, LLC | 251.44K | 0 |
| Two Sigma Investments, LP | 240.82K | ▲ 240.82K |
| Millennium Management LLC | 239.70K | ▲ 129.68K |
| Renaissance Technologies LLC | 228.90K | ▼ 800 |
Held by 33 ETFs
Biggest fund positions in DERM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Toledano Miranda Jayne | other | 50,000 |
| Jul 1, 26 | Smith Justin Adam | other | 50,000 |
| Jul 1, 26 | Herskowitz Neil | other | 50,000 |
| Jun 25, 26 | Toledano Miranda Jayne | other | 10,000 |
| Jun 25, 26 | Smith Justin Adam | other | 10,000 |
| Jun 25, 26 | Herskowitz Neil | other | 10,000 |
| Jun 25, 26 | Pearce Michael Cooper | other | 10,000 |
| Jun 25, 26 | ROSENWALD LINDSAY A MD | other | 10,000 |
| Apr 22, 26 | Alloush Ramsey | other | 46,863 |
| Apr 22, 26 | Alloush Ramsey | other | 62,795 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DERM coverage
Recent articles, reports, and earnings notes.
Want a deeper read on DERM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Journey Medical Corporation (DERM) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com · Nov 12
Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
globenewswire.com · Nov 5
Vireo Growth (OTCMKTS:VREOD) vs. Journey Medical (NASDAQ:DERM) Critical Contrast
defenseworld.net · Oct 6
Journey Medical: A Small Pharma With A Large Growth Opportunity
seekingalpha.com · Sep 19
Journey Medical Corporation to Participate in September 2026 Investor Conferences
globenewswire.com · Sep 8
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
zacks.com · Aug 25
Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction
seekingalpha.com · Aug 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
